The HOPE Study and MICRO-HOPE Substudy

Patel, Vinod; Panja, S; Venkataraman, Asok

doi:10.1177/14746514010010010701

Cited by 7 publications

(4 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Marked differences in arterial and venous oxygen saturation levels and in arteriovenous difference were found between patients with and without sartan therapy. In the past, numerous studies dealt with the positive effects of ACE inhibitors and AT-II antagonists on possible cardiovascular outcomes 21 . The Heart and Outcomes Prevention Evaluation (HOPE) study confirmed vasculoprotective effects arising from treatment with ramipril.…”

Section: Discussionmentioning

confidence: 99%

“…Marked differences in arterial and venous oxygen saturation levels and in arteriovenous difference were found between patients with and without sartan therapy. In the past, numerous studies dealt with the positive effects of ACE inhibitors and AT-II antagonists on possible cardiovascular outcomes [21]. The Heart ▶ Table 2 Medians of the venous oxygen saturation, arterial oxygen saturation and the AV difference for the different degrees of severity of nonproliferative diabetic retinopathy and for proliferative diabetic retinopathy.…”

Section: Sartansmentioning

confidence: 99%

“…Es fanden sich bei den venösen und arteriellen Sauerstoffsättigungswerten sowie bei der arteriovenösen Differenz deutliche Unterschiede zwischen Patienten mit und ohne Sartan-Therapie. In der Vergangenheit beschäftigten sich zahlreiche Arbeiten mit den positiven Effekten von ACE-Hemmern und Angiotensin-II-Antagonisten auf mögliche kardiovaskuläre Auswirkungen 21 . Die HOPE-Studie (HOPE: Heart and Outcomes Prevention Evaluation) bestätigte vaskuloprotektive Wirkungen, die von der Therapie mit Ramipril ausgingen.…”

Section: Diskussionunclassified

See 2 more Smart Citations

The Oxygen Saturation in the Retinal Vessels of Patients with Diabetes Mellitus – The Search for Determinants

Stodtmeister

Mielke

Sandner

2021

Klin Monbl Augenheilkd

View full text Add to dashboard Cite

Introduction Oxygen saturation in retinal vessels can be non-invasively measured by a new method. It is known that oxygen extraction is lowered in diabetic retinopathy. In the cross-sectional study presented here, it has been investigated whether diabetes-specific changes and typical accompanying diseases could influence the measurements in oximetry. Methods During a time span of seven months, 237 diabetics were included who came to our clinic for an intravitreal injection, who met the inclusion criteria, who showed no exclusion criteria and gave written consent. 203 eyes of 203 patients were evaluated. The oxygen saturation (SO2) was measured in digitally stored fundus images taken with a fundus camera (Zeiss 450 FF). In its illumination beam, a filter was inserted with two transmission maxima at 584 nm and 610 nm (bandwidth 10 nm). With the program “Oximetry” (Imedos Systems, Jena, Germany), the venous and the arterial SO2 were measured. The values were stored in a spreadsheet. Diabetes related data, clinical parameters and accompanying diseases were documented in the predefined scheme. Results In the whole patient sample, the venous oxygen saturation (vSO2) was 69 ± 12%, the arterial saturation (aSO2) 99 ± 5% and the arteriovenous difference 31 ± 9%. A statistically significant association could not be found between the measurement values of oximetry and age, duration of diabetes and HbA1c (Kruskal-Wallis ANOVA: p > 0.05). The differences in oximetry values between units of analysis (UOA) e.g. hypertension and non units of analysis (NOA) were analysed. Descriptive testing showed significant differences in vSO2% in the following units of analysis: allergies n = 47: UOA vs. NUOA: 64 vs. 69 (t test: p < 0.02); sartan therapy n = 46: UOA vs. NUOA: 64 vs. 70 (p = 0.003); state after intravitreal injections n = 144: 68 vs. 71 (p = 0.02). Oxygen extraction from the retinal capillaries was improved in patients who had injections with VEGF inhibitors. An improvement in oxygen extraction is also seen in patients with allergies and hypertension in comparison to those without these units of analysis. Conclusion The clinically observed improvement in the retinal state situation after intravitreal injections with VEGF inhibitors may be seen in association with the improved oxygen extraction. It seems reasonable to study whether a switch to sartans in the therapy of hypertension may improve retinal function.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Marked differences in arterial and venous oxygen saturation levels and in arteriovenous difference were found between patients with and without sartan therapy. In the past, numerous studies dealt with the positive effects of ACE inhibitors and AT-II antagonists on possible cardiovascular outcomes [21]. The Heart ▶ Table 2 Medians of the venous oxygen saturation, arterial oxygen saturation and the AV difference for the different degrees of severity of nonproliferative diabetic retinopathy and for proliferative diabetic retinopathy.…”

Section: Sartansmentioning

confidence: 99%

Section: Diskussionunclassified

See 1 more Smart Citation

The Oxygen Saturation in the Retinal Vessels of Patients with Diabetes Mellitus – The Search for Determinants

Stodtmeister

Mielke

Sandner

2021

Klin Monbl Augenheilkd

View full text Add to dashboard Cite

show abstract

“…The prodiabetic effect of some β-blockers is concerning since diabetes increases the risk of adverse cardiovascular outcomes in hypertensive patients (Heart Outcomes Prevention Evaluation (HOPE) Study Investigators 2001; UK Prospective Diabetes Study (UKPDS) Group 1998). Studies have shown that patients being treated with β-blockers have as much as 32 % higher risk of developing diabetes when compared with individuals taking no drugs (Gress et al 2000; Messerli et al 2008).…”

Section: Introductionmentioning

confidence: 99%

Novel plasma biomarker of atenolol-induced hyperglycemia identified through a metabolomics-genomics integrative approach

et al. 2016

View full text Add to dashboard Cite

Introduction While atenolol is an effective antihypertensive agent, its use is also associated with adverse events including hyperglycemia and incident diabetes that may offset the benefits of blood pressure lowering. By combining metabolomic and genomic data acquired from hypertensive individuals treated with atenolol, it may be possible to better understand the pathways that most impact the development of an adverse glycemic state. Objective To identify biomarkers that can help predict susceptibility to blood glucose excursions during exposure to atenolol. Methods Plasma samples acquired from 234 Caucasian participants treated with atenolol in the Pharmacogenomic Evaluation of Antihypertensive Responses trial were analyzed by gas chromatography Time-Of-Flight Mass Spectroscopy. Metabolomics and genomics data were integrated by first correlating participant’s metabolomic profiles to change in glucose after treatment with atenolol, and then incorporating genotype information from genes involved in metabolite pathways associated with glucose response. Results Our findings indicate that the baseline level of β-alanine was associated with glucose change after treatment with atenolol (Q = 0.007, β = 2.97 mg/dL). Analysis of genomic data revealed that carriers of the G allele for SNP rs2669429 in gene DPYS, which codes for dihydropyrimidinase, an enzyme involved in β-alanine formation, had significantly higher glucose levels after treatment with atenolol when compared with non-carriers (Q = 0.05, β = 2.76 mg/dL). This finding was replicated in participants who received atenolol as an add-on therapy (P = 0.04, β = 1.86 mg/dL). Conclusion These results suggest that β-alanine and rs2669429 may be predictors of atenolol-induced hyperglycemia in Caucasian individuals and further investigation is warranted.

show abstract